40283-05-4

Basic information

• Product Name: Benzenebutanol, 4-fluoro-
• CAS NO: 40283-05-4
• Molecular Formula: C10H13FO
• Molecular Weight: 168.211
• Mol File: 40283-05-4.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Benzenebutanol, 4-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenebutanol, 4-fluoro-(40283-05-4)
• EPA Substance Registry System: Benzenebutanol, 4-fluoro-(40283-05-4)

Safety Data

• Hazardous Substances Data: 40283-05-4(Hazardous Substances Data)

Upstream product

• 70250-73-6 4-(4-fluorophenyl)but-3-yn-1-ol 
• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 
• 1736-67-0 4-fluorophenylacetaldehyde 
• 20637-05-2 methyl 4-(4-fluorophenyl)butanoate 
• 589-06-0 4-(4-fluorophenyl)butanoic acid 
• 1693-05-6 ethyl 4-(4'-fluorophenyl)butanoate 

Downstream Products

• 220728-25-6 2-[4-(4-fluorophenyl)butyl]isoindoline-1,3-dione 
• 1281859-92-4 6-benzyl-1-(4-(4-fluorophenyl)butyl)-3-hydroxy-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1281859-89-9 6-benzyl-1-(4-(4-fluorophenyl)butyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1281859-86-6 6-benzyl-1-(4-(4-fluorophenyl)butyl)-5-isopropyl-3-(2-oxo-2-phenylethyl)pyrimidine-2,4(1H,3H)-dione 
• 1281859-81-1 6-benzyl-1-(4-(4-fluorophenyl)butoxymethyl)-3-hydroxy-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1281859-78-6 6-benzyl-1-(4-(4-fluorophenyl)butoxymethyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 1089672-20-7 4-(4-fluorophenyl)butyl methanesulfonate 
• 925442-73-5 4-(4-fluorophenyl)butan-1-al 
• 89347-14-8 6-(4-Fluoro-phenyl)-hexanoic acid (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl ester 
• 89326-71-6 ethyl 2-ethoxycarbonyl-6-(4'-fluorophenyl)hexanoate 
• 89326-76-1 6-(4-Fluoro-phenyl)-hexanoyl chloride 
• 89326-72-7 6-(4'-fluorophenyl)hexanoic acid 

Relevant articles and documents

Discovery and evaluation of nNav1.5 sodium channel blockers with potent cell invasion inhibitory activity in breast cancer cells

Voltage-gated sodium channels (VGSC) are a well-established drug target for anti-epileptic, anti-arrhythmic and pain medications due to their presence and the important roles that they play in excitable cells. Recently, their presence has been recognized in non-excitable cells such as cancer cells and their overexpression has been shown to be associated with metastatic behavior in a variety of human cancers. The neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5) is overexpressed in the highly aggressive human breast cancer cell line, MDA-MB-231. The activity of nNav1.5 is known to promote the breast cancer cell invasion in vitro and metastasis in vivo, and its expression in primary mammary tumors has been associated with metastasis and patient death. Metastasis development is responsible for the high mortality of breast cancer and currently there is no treatment available to specifically prevent or inhibit breast cancer metastasis. In the present study, a 3D-QSAR model is used to assist the development of low micromolar small molecule VGSC blockers. Using this model, we have designed, synthesized and evaluated five small molecule compounds as blockers of nNav1.5-dependent inward currents in whole-cell patch-clamp experiments in MDA-MB-231 cells. The most active compound identified from these studies blocked sodium currents by 34.9 ± 6.6% at 1 μM. This compound also inhibited the invasion of MDA-MB-231 cells by 30.3 ± 4.5% at 1 μM concentration without affecting the cell viability. The potent small molecule compounds presented here have the potential to be developed as drugs for breast cancer metastasis treatment.

GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE

The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS

The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.